Hematology

Filter

EHA Congress Wrap

June 2026

The European Hematology Association (EHA) Congress 2026 brought together haematology experts from around the world to share the latest…

EAHAD 2024 – Interview with the Congress President

EMJ sat down with EAHAD President, Wolfgang Miesbach, live at this year’s congress in Frankfurt, Germany. Miesbach highlighted key…

EAHAD 2024 - Key Reflections from the Congress President

Live from EAHAD 2024, Wolfgang Miesbach, Congress President, shares a glimpse of the event, emphasises stand-out sessions from the…

CME-accredited Webinar: The Use of Angiotensin II in Vasodilatory Shock

A CME-accredited webinar covers vasodilatory shock, the current vasoactive agents, and acritical evaluation of emerging therapies.

Autologous Transplant or Chimeric Antigen Receptor T Cell Therapy for Patients with Relapsed/Refractory Large B-cell Lymphoma: How to Choose?

Expert Madiha Iqbal, Consultant and Assistant Professor of Medicine, Mayo Clinic, Jacksonville, Florida, USA, presents on the treatment…

Update on Challenges in Diagnosis and Treatment of Myeloid Neoplasms with Systemic Mastocytosis

Concurrent systemic mastocytosis (SM) may often be missed in patients with myeloid neoplasms, such as, chronic myelomonocytic…

Chronic Lymphocytic Leukemia (CLL) and Beyond: Management of the Infection Burden

The overall survival of patients with chronic lymphocytic leukemia (CLL) has improved significantly over the years; however, the clinical…

Evolving the treatment paradigm in cold agglutinin disease (CAD): Challenges and opportunities for optimal management

Prof. Alexander Röth (Chair), Prof. Wilma Barcellini, Prof. Josephine Vos and Prof. Bernd Jilma, will discuss about the evolving treatment paradigm in cold agglutinin disease (CAD): challenges and opportunities for optimal management.

What to do when CAR Ts are not the most appropriate option in 2L DLBCL: Current treatment options for transplant-ineligible patients

An innovative session highlighting patient-focused decision-making and a dynamic debate on current 2L DLBCL treatment options.

Loading posts...

« Previous 1 2 3 4 5 6 … 10 Next »